ATE252639T1 - Modifizierter, das dorsalgewebe beeinflussender faktor - Google Patents

Modifizierter, das dorsalgewebe beeinflussender faktor

Info

Publication number
ATE252639T1
ATE252639T1 AT98936850T AT98936850T ATE252639T1 AT E252639 T1 ATE252639 T1 AT E252639T1 AT 98936850 T AT98936850 T AT 98936850T AT 98936850 T AT98936850 T AT 98936850T AT E252639 T1 ATE252639 T1 AT E252639T1
Authority
AT
Austria
Prior art keywords
factor affecting
modified factor
dorsal tissue
muteins
dorsal
Prior art date
Application number
AT98936850T
Other languages
English (en)
Inventor
Neil Stahl
Richard M Harland
Aris N Economides
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE252639T1 publication Critical patent/ATE252639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98936850T 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor ATE252639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,236 US6075007A (en) 1997-07-17 1997-07-17 Modified noggin polypeptide and compositions
PCT/US1998/014603 WO1999003996A1 (en) 1997-07-17 1998-07-17 Modified dorsal tissue affecting factor and compositions

Publications (1)

Publication Number Publication Date
ATE252639T1 true ATE252639T1 (de) 2003-11-15

Family

ID=25407592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936850T ATE252639T1 (de) 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor

Country Status (9)

Country Link
US (3) US6075007A (de)
EP (1) EP1003860B1 (de)
JP (1) JP4181300B2 (de)
AT (1) ATE252639T1 (de)
AU (1) AU735851B2 (de)
CA (1) CA2296769C (de)
DE (1) DE69819167T2 (de)
IL (2) IL134042A0 (de)
WO (1) WO1999003996A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105477A1 (de) 1998-08-20 2001-06-13 Regeneron Pharmaceuticals, Inc. Dcr5: ein protein, das an bmp bindet, und verwendungen davon
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
WO2002054940A2 (en) * 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
MXPA05009805A (es) * 2003-03-14 2006-04-18 Celltech R & D Inc Ligandos para proteinas de enlace tgf-beta y usos de los mismos.
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
CN102586170B (zh) * 2004-07-09 2019-11-29 维亚希特公司 前原条和中内胚层细胞
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
EP2421957B1 (de) * 2009-04-22 2020-11-18 Viacyte, Inc. Zellzusammensetzungen aus entdifferenzierten neuprogrammierten zellen
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012093704A1 (ja) * 2011-01-07 2012-07-12 中外製薬株式会社 抗体の物性を改善させる方法
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP3712168A3 (de) 2011-12-28 2020-10-14 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten
AU2020225319B2 (en) * 2019-02-19 2025-05-29 Medizinische Universität Wien New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
JP7848994B2 (ja) * 2021-12-28 2026-04-21 国立大学法人山口大学 ノギンタンパク質を分泌する細胞およびそれを用いたオルガノイドの作製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
ATE140966T1 (de) 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
ES2149823T3 (es) * 1992-09-03 2000-11-16 Univ California Factor y composiciones que afectan al tejido dorsal.
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions

Also Published As

Publication number Publication date
JP2001510044A (ja) 2001-07-31
EP1003860B1 (de) 2003-10-22
DE69819167T2 (de) 2004-07-22
CA2296769A1 (en) 1999-01-28
DE69819167D1 (de) 2003-11-27
US20030129703A1 (en) 2003-07-10
US6500640B1 (en) 2002-12-31
AU8570898A (en) 1999-02-10
JP4181300B2 (ja) 2008-11-12
IL134042A0 (en) 2001-04-30
IL134042A (en) 2006-12-10
CA2296769C (en) 2008-01-15
WO1999003996A1 (en) 1999-01-28
AU735851B2 (en) 2001-07-19
HK1026229A1 (en) 2000-12-08
EP1003860A1 (de) 2000-05-31
US6075007A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL106894A0 (en) Dorsal tissue affecting factor and compositions
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
WO1999051731A3 (en) Maize histone deacetylases and their use
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
IT1293691B1 (it) Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni.
NO20013102L (no) Gener, proteiner og deres anvendelse
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
DE50009838D1 (de) Humanes antibiotisches protein
IL139604A0 (en) Novel peptides
PE20399A1 (es) Muteina ob
DE69737265D1 (de) Herstellung nickelenthaltenden, gesinterten, verfestigten, feritischen rostfreien stahls
EP1096927A4 (de) Zusammensetzung für stressbehandlung
IT242987Y1 (it) Guarnitura per mobili.
NO20013101D0 (no) Ytre overflateproteiner, deres gener og deres anvendelse
DE10081621D2 (de) Promotorsystem, dessen Herstellung und Verwendung
DE69828906D1 (de) Herstellung von 1,3 propandiolestern
ITBO970602A0 (it) Apparecchiatura per trattamento di dialisi.
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
GB9723824D0 (en) Cytostatic agents
NO179773C (no) Fjernbar, ortopedisk brudd-stabilisator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003860

Country of ref document: EP

REN Ceased due to non-payment of the annual fee